# Module 01: Foundations - Obesity Medicine & Incretin Physiology

GLP-1 Receptor Agonists for Obesity Management: A Comprehensive Provider Course

---

---
type: Lesson
status: Complete
audience: Provider
cme: true
module: "[[Module 01 - Foundations (Obesity Medicine & Incretin Physiology)]]"
time_estimate_min: 15
format: video
learning_objectives:
  - Define obesity using BMI, waist circumference, and comorbidity criteria
  - Recognize obesity as a chronic, relapsing neurometabolic disease
  - Identify limitations of lifestyle intervention alone for long-term weight management
last_reviewed:
related:
  - "[[Lesson 1.2 - Neuroendocrine Regulation of Appetite]]"
sources:
---

# Lesson 1.1 — Obesity as a Chronic Disease

## Learner level
- Entry-level provider with basic clinical knowledge
- No prior obesity medicine training assumed

## Time + format
- Time: 15 min
- Format: Video lecture + key visual

## Learning objectives (measurable)
1. Define obesity using current diagnostic criteria (BMI ≥30, or ≥27 with comorbidities)
2. Explain why obesity is classified as a chronic, relapsing disease (not a lifestyle choice)
3. Cite evidence showing long-term failure rates of lifestyle-only interventions

## Hook (clinical scenario / why this matters)
- "Your patient lost 40 lbs with diet and exercise, but regained it all within 2 years. They feel like a failure. What do you tell them?"

## Prior knowledge checkpoint
- Basic understanding of BMI calculation
- Familiarity with common obesity-related comorbidities (T2DM, HTN, OSA, NAFLD)

## Core content (chunked)

### Chunk 1 — Diagnostic criteria
- BMI classification: overweight (25-29.9), obesity class I (30-34.9), II (35-39.9), III (≥40)
- Waist circumference thresholds (>40" men, >35" women) as cardiometabolic risk marker
- Edmonton Obesity Staging System (functional impact)

### Chunk 2 — Obesity as disease, not choice
- AMA recognition (2013): obesity as a disease requiring treatment
- Chronic, relapsing nature — comparable to hypertension, diabetes
- Genetic heritability (~40-70%)
- Environmental obesogens and food environment factors

### Chunk 3 — Why lifestyle alone often fails
- Metabolic adaptation: decreased REE after weight loss
- Hormonal changes: increased ghrelin, decreased leptin/PYY post-weight loss
- Look AHEAD trial: intensive lifestyle achieved ~6% sustained loss; 50%+ regain by 4 years

## Key visual(s) (figures, tables, diagrams)
- Figure: "The Weight Regain Cycle" — biology fights back
- Table: BMI classification with comorbidity risk stratification

## Clinical pearls (high yield)
- "Obesity is a disease of energy regulation, not willpower"
- Sustained weight loss >10% with lifestyle alone occurs in <5% of patients at 5 years
- Framing matters: "Your biology is working against you — we have tools to help"

## Knowledge checks (with rationales)
1. **Question:** What percentage of weight loss is typically sustained at 5 years with lifestyle intervention alone?
   - **Answer:** <5-10%
   - **Rationale:** Metabolic adaptation and hormonal changes drive weight regain in most patients
   - **Source:** Look AHEAD Research Group, NEJM 2013

2. **Question:** Which organization officially recognized obesity as a disease in 2013?
   - **Answer:** American Medical Association (AMA)
   - **Rationale:** This shifted the paradigm from "lifestyle problem" to "chronic disease requiring treatment"
   - **Source:** AMA House of Delegates, 2013

## Take-home summary (3 takeaways)
- Obesity is a chronic, relapsing neurometabolic disease — not a character flaw
- Biology (hormones, genetics, metabolic adaptation) drives weight regain after loss
- Pharmacotherapy addresses the biological drivers that lifestyle cannot overcome

## Sources
- Look AHEAD Research Group. NEJM 2013.
- AMA House of Delegates Resolution 420 (A-13), 2013.
- Schwartz MW et al. Obesity pathogenesis: An Endocrine Society scientific statement. Endocr Rev 2017.


---

---
type: Lesson
status: Complete
audience: Provider
cme: true
module: "[[Module 01 - Foundations (Obesity Medicine & Incretin Physiology)]]"
time_estimate_min: 15
format: video
learning_objectives:
  - Identify key appetite-regulating hormones and their sites of action
  - Explain the roles of the hypothalamus and brainstem in energy homeostasis
  - Describe how GLP-1 RAs target these regulatory pathways
last_reviewed:
related:
  - "[[Lesson 1.1 - Obesity as a Chronic Disease]]"
  - "[[Lesson 1.3 - The Incretin Effect (GLP-1 & GIP Physiology)]]"
sources:
---

# Lesson 1.2 — Neuroendocrine Regulation of Appetite

## Learner level
- Provider with basic physiology knowledge
- Building toward incretin pharmacology

## Time + format
- Time: 15 min
- Format: Video lecture + diagram

## Learning objectives (measurable)
1. Name the key orexigenic (hunger) and anorexigenic (satiety) hormones
2. Locate the hypothalamic nuclei involved in energy balance (ARC, PVN, LH)
3. Explain the gut-brain axis and how peripheral signals reach the CNS

## Hook (clinical scenario / why this matters)
- "Why does your patient feel ravenously hungry after losing weight? Understanding the biology helps you explain — and treat — the problem."

## Prior knowledge checkpoint
- Basic neuroanatomy (hypothalamus location/function)
- Concept of hormones as signaling molecules

## Core content (chunked)

### Chunk 1 — The hunger/satiety hormones
- **Orexigenic (increase hunger):**
  - Ghrelin (stomach) — "hunger hormone," rises before meals
  - NPY/AgRP neurons (hypothalamus) — drive feeding behavior
- **Anorexigenic (decrease hunger):**
  - Leptin (adipose) — long-term energy stores signal
  - GLP-1, PYY, CCK (gut) — meal-induced satiety signals
  - POMC/CART neurons (hypothalamus) — suppress appetite

### Chunk 2 — Central control: the hypothalamus
- Arcuate nucleus (ARC): integrates peripheral signals (leptin, insulin, ghrelin)
- Paraventricular nucleus (PVN): outputs to autonomic system, thyroid axis
- Lateral hypothalamus (LH): "feeding center"
- Brainstem (NTS): receives vagal afferents from gut

### Chunk 3 — The gut-brain axis
- Vagus nerve: primary conduit for gut hormone signals
- GLP-1 acts both peripherally (pancreas, gut motility) and centrally (hypothalamus, brainstem)
- Blood-brain barrier: some hormones cross; GLP-1 RAs designed to penetrate CNS

## Key visual(s) (figures, tables, diagrams)
- Diagram: Gut-brain axis showing hormone sources and CNS targets
- Table: Key appetite hormones — source, effect, clinical relevance

## Clinical pearls (high yield)
- Ghrelin rises after weight loss — this is why patients feel hungrier
- Leptin resistance in obesity: high levels but blunted CNS response
- GLP-1 RAs work partly by enhancing satiety signals the brain already uses

## Knowledge checks (with rationales)
1. **Question:** Which hormone increases before meals and drives hunger?
   - **Answer:** Ghrelin
   - **Rationale:** Ghrelin is the only known orexigenic gut hormone; levels rise pre-meal and fall post-meal
   - **Source:** Cummings DE et al. NEJM 2002

2. **Question:** Where does GLP-1 act in the CNS to reduce appetite?
   - **Answer:** Hypothalamus (arcuate nucleus) and brainstem (nucleus tractus solitarius)
   - **Rationale:** GLP-1 receptors in these areas mediate satiety and food intake reduction
   - **Source:** Turton MD et al. Nature 1996

## Take-home summary (3 takeaways)
- Appetite is regulated by a complex interplay of gut hormones and CNS circuits
- Weight loss triggers hormonal changes (↑ghrelin, ↓leptin sensitivity) that promote regain
- GLP-1 RAs leverage the body's natural satiety pathways to reduce hunger

## Sources
- Cummings DE, Schwartz MW. Genetics and pathophysiology of human obesity. Annu Rev Med 2003.
- Turton MD et al. A role for GLP-1 in the central regulation of feeding. Nature 1996.
- Schwartz MW et al. Central nervous system control of food intake. Nature 2000.


---

---
type: Lesson
status: Complete
audience: Provider
cme: true
module: "[[Module 01 - Foundations (Obesity Medicine & Incretin Physiology)]]"
time_estimate_min: 15
format: video
learning_objectives:
  - Define the incretin effect and its clinical significance
  - Compare the physiologic actions of GLP-1 vs GIP
  - Explain why native GLP-1 has a short half-life and how analogs overcome this
last_reviewed:
related:
  - "[[Lesson 1.2 - Neuroendocrine Regulation of Appetite]]"
  - "[[Lesson 1.4 - Why Medications Matter (Setpoint Theory & Metabolic Adaptation)]]"
  - "[[Semaglutide (Wegovy-Ozempic)]]"
  - "[[Tirzepatide (Zepbound-Mounjaro)]]"
sources:
---

# Lesson 1.3 — The Incretin Effect (GLP-1 & GIP Physiology)

## Learner level
- Provider ready to understand pharmacology rationale
- Foundation for medication modules

## Time + format
- Time: 15 min
- Format: Video lecture + comparison table

## Learning objectives (measurable)
1. Define the incretin effect and quantify its contribution to insulin secretion
2. List the physiologic actions of GLP-1 beyond insulin secretion
3. Compare GLP-1 and GIP: similarities, differences, and therapeutic implications
4. Explain DPP-4 degradation and how GLP-1 analogs achieve longer half-lives

## Hook (clinical scenario / why this matters)
- "Oral glucose triggers more insulin release than IV glucose at the same blood glucose level. Why? Understanding this 'incretin effect' is key to how these medications work."

## Prior knowledge checkpoint
- Basic insulin/glucagon physiology
- Understanding of peptide hormone signaling

## Core content (chunked)

### Chunk 1 — The incretin effect defined
- Incretin effect: ~50-70% of postprandial insulin secretion is gut-mediated
- Discovered by comparing oral vs IV glucose tolerance tests
- Two main incretins: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide)

### Chunk 2 — GLP-1 physiology (multi-organ effects)
- **Source:** L-cells (ileum, colon) — secreted in response to nutrients
- **Pancreas:** Glucose-dependent insulin secretion (↑), glucagon suppression (↓)
- **Stomach:** Delayed gastric emptying → prolonged satiety
- **Brain:** Appetite suppression via hypothalamus/brainstem GLP-1R
- **Heart:** Potential cardioprotective effects (improved endothelial function)
- **Half-life:** Native GLP-1 = 1-2 minutes (rapidly degraded by DPP-4)

### Chunk 3 — GIP physiology
- **Source:** K-cells (duodenum, jejunum)
- **Pancreas:** Glucose-dependent insulin secretion
- **Adipose:** May promote lipid storage (historically seen as negative)
- **Bone:** Potential anti-resorptive effects
- **Brain:** Emerging evidence for appetite/reward pathway modulation
- **Key insight:** GIP alone less effective for weight loss; combined with GLP-1 = synergistic

### Chunk 4 — From native hormone to therapeutic analog
- DPP-4 problem: native GLP-1 half-life too short for therapy
- Solutions:
  - DPP-4 inhibitors (sitagliptin, etc.): boost endogenous GLP-1 (modest effect)
  - GLP-1 receptor agonists: DPP-4-resistant analogs with extended half-lives
- Semaglutide: albumin binding + structural modifications → t½ ~1 week
- Tirzepatide: dual GLP-1/GIP agonist → enhanced efficacy

## Key visual(s) (figures, tables, diagrams)
- Figure: The incretin effect — oral vs IV glucose insulin response
- Table: GLP-1 vs GIP comparison (source, actions, therapeutic relevance)

## Clinical pearls (high yield)
- The incretin effect is blunted in T2DM — rationale for incretin-based therapy
- GLP-1's glucose-dependent action = low hypoglycemia risk (unlike sulfonylureas)
- Tirzepatide's dual agonism may explain superior weight loss vs semaglutide

## Knowledge checks (with rationales)
1. **Question:** What percentage of postprandial insulin secretion is attributed to the incretin effect?
   - **Answer:** 50-70%
   - **Rationale:** This explains why oral glucose stimulates more insulin than IV glucose
   - **Source:** Nauck MA et al. Diabetologia 1986

2. **Question:** Why does native GLP-1 have a half-life of only 1-2 minutes?
   - **Answer:** Rapid degradation by the enzyme DPP-4
   - **Rationale:** This necessitated development of DPP-4-resistant analogs for therapeutic use
   - **Source:** Deacon CF et al. Diabetes 1995

3. **Question:** Which drug class activates both GLP-1 and GIP receptors?
   - **Answer:** Tirzepatide (dual GLP-1/GIP agonist)
   - **Rationale:** Dual agonism produces synergistic effects on weight and glycemia
   - **Source:** Frías JP et al. NEJM 2021

## Take-home summary (3 takeaways)
- The incretin effect accounts for most postprandial insulin secretion and is impaired in T2DM
- GLP-1 has multi-organ effects: pancreas, stomach, brain, heart — all relevant to obesity treatment
- Modern GLP-1 RAs are engineered to resist DPP-4 degradation, enabling once-weekly dosing

## Sources
- Nauck MA et al. Incretin effects of increasing glucose loads. Diabetologia 1986.
- Drucker DJ. Mechanisms of action and therapeutic application of GLP-1. Cell Metab 2018.
- Frías JP et al. Tirzepatide vs semaglutide (SURPASS-2). NEJM 2021.


---

---
type: Lesson
status: Complete
audience: Provider
cme: true
module: "[[Module 01 - Foundations (Obesity Medicine & Incretin Physiology)]]"
time_estimate_min: 15
format: video
learning_objectives:
  - Explain setpoint theory and its implications for weight management
  - Describe metabolic adaptation following weight loss
  - Articulate the rationale for pharmacotherapy as a chronic disease treatment
last_reviewed:
related:
  - "[[Lesson 1.1 - Obesity as a Chronic Disease]]"
  - "[[Lesson 1.3 - The Incretin Effect (GLP-1 & GIP Physiology)]]"
sources:
---

# Lesson 1.4 — Why Medications Matter (Setpoint Theory & Metabolic Adaptation)

## Learner level
- Provider integrating foundational concepts
- Preparing to discuss treatment rationale with patients

## Time + format
- Time: 15 min
- Format: Video lecture + clinical case

## Learning objectives (measurable)
1. Define the "body weight setpoint" concept and its biological basis
2. Quantify metabolic adaptation after weight loss (REE reduction)
3. Explain why chronic pharmacotherapy is appropriate for a chronic disease
4. Counter common objections: "Isn't this just a crutch?"

## Hook (clinical scenario / why this matters)
- "Your patient asks: 'Why do I need medication? Can't I just try harder?' This lesson gives you the science to answer compassionately and accurately."

## Prior knowledge checkpoint
- Lessons 1.1-1.3 content (obesity as disease, hormones, incretins)

## Core content (chunked)

### Chunk 1 — Setpoint theory
- Body defends a "defended weight range" through hormonal and neural feedback
- Setpoint influenced by genetics, early nutrition, weight history
- Weight loss triggers compensatory responses to restore the setpoint
- Analogy: thermostat — body fights to return to its "set temperature"

### Chunk 2 — Metabolic adaptation (the Biggest Loser study)
- Landmark: Fothergill et al. (Obesity 2016) — Biggest Loser contestants
- Findings 6 years post-competition:
  - Mean regain: 70% of lost weight
  - REE reduced by ~500 kcal/day below predicted (persistent metabolic adaptation)
  - Leptin remained suppressed
- Clinical implication: biology drives regain, not lack of willpower

### Chunk 3 — The case for chronic pharmacotherapy
- Obesity = chronic disease → requires chronic treatment
- Analogy: We don't stop antihypertensives when BP normalizes
- GLP-1 RAs address the biological drivers:
  - Reduce hunger (CNS effects)
  - Improve satiety (gastric emptying)
  - May help "reset" defended weight over time
- Stopping medication → weight regain (STEP 4 withdrawal data)

### Chunk 4 — Addressing patient/provider hesitations
- "It's a crutch" → "It's a treatment for a biological condition"
- "It's the easy way out" → "It works *with* lifestyle, not instead of it"
- "What about long-term?" → Chronic disease model; ongoing data supports safety
- Provider bias: obesity often undertreated due to stigma

## Key visual(s) (figures, tables, diagrams)
- Graph: Biggest Loser metabolic adaptation over 6 years
- Diagram: Setpoint defense mechanisms (hormonal, neural, metabolic)

## Clinical pearls (high yield)
- Metabolic adaptation can persist for years — it's not "resetting"
- STEP 4 showed 2/3 of weight loss regained within 1 year of stopping semaglutide
- Framing: "This medication helps your body work with you, not against you"

## Knowledge checks (with rationales)
1. **Question:** In the Biggest Loser study, how much did resting energy expenditure remain suppressed 6 years later?
   - **Answer:** ~500 kcal/day below predicted
   - **Rationale:** Metabolic adaptation persists long-term, contributing to weight regain
   - **Source:** Fothergill E et al. Obesity 2016

2. **Question:** What happened to weight in STEP 4 when semaglutide was withdrawn?
   - **Answer:** Participants regained approximately 2/3 of the weight they had lost
   - **Rationale:** This demonstrates that GLP-1 RAs treat an ongoing condition; stopping treatment allows the underlying biology to reassert
   - **Source:** Rubino D et al. JAMA 2021 (STEP 4)

## Take-home summary (3 takeaways)
- The body actively defends its weight through hormonal and metabolic adaptations
- Metabolic adaptation after weight loss can persist for years and drives regain
- Chronic pharmacotherapy is appropriate because obesity is a chronic disease — just like HTN or T2DM

## Sources
- Fothergill E et al. Persistent metabolic adaptation 6 years after "The Biggest Loser" competition. Obesity 2016.
- Rubino D et al. Effect of continued weekly semaglutide vs placebo (STEP 4). JAMA 2021.
- Rosenbaum M, Leibel RL. Adaptive thermogenesis in humans. Int J Obes 2010.


---


